These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 19003542)

  • 1. Concepts and challenges in quantitative pharmacology and model-based drug development.
    Zhang L; Pfister M; Meibohm B
    AAPS J; 2008 Dec; 10(4):552-9. PubMed ID: 19003542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fostering culture and optimizing organizational structure for implementing model-based drug development.
    Zhang L; Allerheiligen SR; Lalonde RL; Stanski DR; Pfister M
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):146S-150S. PubMed ID: 20881228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
    Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
    Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based drug development: a rational approach to efficiently accelerate drug development.
    Milligan PA; Brown MJ; Marchant B; Martin SW; van der Graaf PH; Benson N; Nucci G; Nichols DJ; Boyd RA; Mandema JW; Krishnaswami S; Zwillich S; Gruben D; Anziano RJ; Stock TC; Lalonde RL
    Clin Pharmacol Ther; 2013 Jun; 93(6):502-14. PubMed ID: 23588322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based clinical drug development in the past, present and future: a commentary.
    Kimko H; Pinheiro J
    Br J Clin Pharmacol; 2015 Jan; 79(1):108-16. PubMed ID: 24527997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
    Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
    AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current role of model-based drug development.
    Suryawanshi S; Zhang L; Pfister M; Meibohm B
    Expert Opin Drug Discov; 2010 Apr; 5(4):311-21. PubMed ID: 22823084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probabilistic risk analysis: improving early drug development decision making.
    Mudd PN; Groenendaal H; Bush MA; Schmith VD
    Clin Pharmacol Ther; 2010 Dec; 88(6):871-5. PubMed ID: 20944562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-based drug development: the road to quantitative pharmacology.
    Zhang L; Sinha V; Forgue ST; Callies S; Ni L; Peck R; Allerheiligen SR
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):369-93. PubMed ID: 16770528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do the top 12 pharmaceutical companies operate safety pharmacology?
    Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
    Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
    Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on the Role of Mathematics in Drug Discovery and Development.
    Allen R; Moore H
    Bull Math Biol; 2019 Sep; 81(9):3425-3435. PubMed ID: 30693431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
    Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
    Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics/pharmacodynamics model-supported early drug development.
    Chen B; Dong JQ; Pan WJ; Ruiz A
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Deterministic Models in Drug Discovery and Development.
    Irurzun-Arana I; Rackauckas C; McDonald TO; Trocóniz IF
    Trends Pharmacol Sci; 2020 Nov; 41(11):882-895. PubMed ID: 33032836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
    Goto A; Abe S; Koshiba S; Yamaguchi K; Sato N; Kurahashi Y
    Drug Metab Pharmacokinet; 2019 Apr; 34(2):148-154. PubMed ID: 30827921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacometrics 2020.
    Gobburu JV
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):151S-157S. PubMed ID: 20881229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated pharmacokinetics and pharmacodynamics in drug development.
    Dingemanse J; Appel-Dingemanse S
    Clin Pharmacokinet; 2007; 46(9):713-37. PubMed ID: 17713971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.